Please assess the completion status of the following clinical trial:

Trial Title: Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any race or ethnicity~* Must have a diagnosis of moderate-to-severe active ulcerative colitis (UC) with inflammation present beyond the rectum and including more than 20 cm of the colon (Mayo score of 6 to 12 points, inclusive ≥ 2 in the endoscopy subscore)~* Must have responded inadequately to oral (with or without topical) 5-ASA treatment (prerequisite oral: at a minimum 4 g/d for 7 days) and must be considered for the first course of systemic corticosteroids; Participants with a UC and a Mayo score of ≥ 9 are also eligible without prior 5-ASA treatment~* Must agree to use acceptable methods of contraception for at least 2 weeks prior to starting any study treatment and to continue until at least 6 months after the last doses of study drugs~* Laboratory results must be within specified limits~* Must be negative for colorectal cancer or any associated lesions~* Must have a negative tuberculosis (TB) test~* Must have a chest x-ray within the 3 months with no clinically significant abnormality, or evidence of current active TB or latent TB~* Must have a negative stool culture~Exclusion Criteria:~* Pregnant, nursing, or planning pregnancy~* Had received previous treatment for UC with the corticosteroids, infliximab, azathioprine/~  6-mercaptopurine (6-MP), cyclosporine, tacrolimus, methotrexate, sirolimus, mycophenolate, any tumor necrosis factor-alpha (TNF-α) inhibitor or receptor constructs that bind to ΤΝF-α (e.g., etanercept or adalimumab) and any other biologic agents~* Frequent (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)~* Use of laxatives or any murine recombinant product~* Had surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage in previous 2 months~* History of colonic obstruction within the previous 6 months~* History of mucosal dysplasia, fistula or colonic resection, adenomatous polyps or stoma, severe, fixed symptomatic stenosis of the large or small intestine~* Had serious infection with previous 2 months, including human immunodeficiency virus (HIV) and hepatitis~* Had organ transplant (with the exception of a corneal transplant)~* Any malignancy within 5 years, including lymphoma~* History of demyelinating disease such as multiple sclerosis or optic neuritis~* Presence or history of congestive heart failure~* Requires chronic and frequent use of antimotility agents for control of diarrhea~* Requires total parenteral nutrition~* Had participated in any other clinical trial within 30 days or intention to participate in another clinical trial during participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Top-Hold (Type: EXPERIMENTAL): Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
- Step-Up (Type: ACTIVE_COMPARATOR): Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).